Discovery of a CNS penetrant small molecule SMN2 splicing modulator with improved tolerability for spinal muscular atrophy
Authors:
Open Access
- 15 October 2020
- journal article
- research article
- Published by Springer Nature in Scientific Reports
- Vol. 10 (1) , 1-16
Abstract
Spinal muscular atrophy (SMA) is a motor neuron disease, typically resulting from loss-of-function mutations in the survival motor neuron 1 (SMN1) gene. Nusinersen/SPINRAZA, a splice-switching oligonucleotide that modulates SMN2 (a paralog of SMN1) splicing and consequently increases SMN protein levels, has a therapeutic effect for SMA. Previously reported small-molecule SMN2 splicing modulators such as risdiplam/EVRYSDI and its analog SMN-C3 modulate not only the splicing of SMN2 but also that of secondary splice targets, including forkhead box protein M1 (FOXM1). Through screening SMA patient-derived fibroblasts, a novel small molecule, designated TEC-1, was identified that selectively modulates SMN2 splicing over three secondary splice targets. TEC-1 did not strongly affect the splicing of FOXM1, and unlike risdiplam, did not induce micronucleus formation. In addition, TEC-1 showed higher selectively on galactosylceramidase and huntingtin gene expression compared to previously reported compounds (e.g., SMN-C3) due to off-target effects on cryptic exon inclusion and nonsense-mediated mRNA decay. Moreover, TEC-1 significantly ameliorated the disease phenotype in an SMA murine model in vivo. Thus, TEC-1 may have promising therapeutic potential for SMA, and our study demonstrates the feasibility of RNA-targeting small-molecule drug development with an improved tolerability profile.Keywords
This publication has 45 references indexed in Scilit:
- Intrathecal administration of nusinersen in adolescent and adult SMA type 2 and 3 patientsJournal of Neurology, 2018
- Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular AtrophyNew England Journal of Medicine, 2017
- How the discovery of ISS-N1 led to the first medical therapy for spinal muscular atrophyGene Therapy, 2017
- Antisense Masking of an hnRNP A1/A2 Intronic Splicing Silencer Corrects SMN2 Splicing in Transgenic MiceThe American Journal of Human Genetics, 2008
- Splicing of a Critical Exon of Human Survival Motor Neuron Is Regulated by a Unique Silencer Element Located in the Last IntronMolecular and Cellular Biology, 2006
- Determinants of Exon 7 Splicing in the Spinal Muscular Atrophy Genes, SMN1 and SMN2The American Journal of Human Genetics, 2006
- In vivo selection reveals combinatorial controls that define a critical exon in the spinal muscular atrophy genesRNA, 2004
- An extended inhibitory context causes skipping of exon 7 of SMN2 in spinal muscular atrophyBiochemical and Biophysical Research Communications, 2004
- A negative element in SMN2 exon 7 inhibits splicing in spinal muscular atrophyNature Genetics, 2003
- Quantitative Analyses of SMN1 and SMN2 Based on Real-Time LightCycler PCR: Fast and Highly Reliable Carrier Testing and Prediction of Severity of Spinal Muscular AtrophyThe American Journal of Human Genetics, 2002